ETF-Investor

LLY Eli Lilly

$1351.12-2.29%2026-11-19 · Quote reference; see timestamp

01Recent performance

PeriodReturnHistorical percentile
Daily-2.29%Insufficient history
WTD—Insufficient history
MTD—Insufficient history
Period comparison through 2026-11-19
YTD—
From 52W high—
IV30—

Loading full research…

02How expensive is the company?

TTM PE 43.85×

TTM PE 43.85× · 76.02%
0%25%50%75%100%

Actual history 19.97Y · 221 month-end samples · 2006-11-30 — 2026-10-30

A comparison with its own history, not a standalone investment decision.

Valuation date 2026-11-19 · Futu market snapshot
Historical valuation chart
1996-11-292026-10-30

PB 31.56×

PB 31.56× · 69.17%
0%25%50%75%100%

Actual history 19.97Y · 240 month-end samples · 2006-11-30 — 2026-10-30

PB is affected by buybacks and equity structure; it is not a standalone trade signal.

Valuation date 2026-11-19 · Futu market snapshot
Historical valuation chart
1996-11-292026-10-30

03Earnings outlook

Forward PE33.03×
Expected EPS growth—

Forward PE · Futu · 2026-11-01

No verified comparable EPS growth forecast. Growth is not inferred from valuation ratios.

No verified comparable Forward PE history; no percentile scale is shown.

04ETFs holding the company

Loading full research…

05Peers & similar companies

Peers and similar companies first, followed by common stocks where needed.

Watch
ABBV——Similar business————————
AMGN——Similar business————————
BIIB——Similar business————————
GILD——Similar business————————
JNJ——Similar business————————
MRK——Similar business————————
PFE——Similar business————————
REGN——Similar business————————
UTHR——Similar business————————
VRTX——Similar business————————

Loading existing stock data…

Percentiles use each company’s own history; actual years appear beside values. Missing data is shown as —. Quote and valuation dates may differ; hover over values for available dates.

06Understand the company

The business in one sentence
Lilly develops and sells prescription drugs for areas including diabetes, obesity, oncology and immunology. Mounjaro and Zepbound both use tirzepatide.

How it earns money
Drug sales generate most revenue. Tirzepatide products have been a major growth driver; prescriptions, supply, realized prices and reimbursement coverage all affect sales.

Why customers choose it · Research perspective
Clinical efficacy and safety, approved indications, payer coverage and reliable supply shape treatment choices. Competing approvals or payer changes can affect volume and realized prices differently.

What to watch next · Research perspective
Watch Mounjaro and Zepbound sales and the effects of volume and price, then key trial or approval milestones. These explain current growth and inform the next set of product opportunities.

Sources

Eli Lilly · 2025 Form 10-K

Sources checked

For research, not personal investment advice.

PASSWORD-FREE ACCESS

Continue with email

We’ll send you a secure sign-in link. No password required.

By continuing, you agree to the Terms and acknowledge the Privacy Policy.